Replies to post #17395 on Ariad Pharmaceuticals Inc fka ARIA

[BTH]

I'm also assuming that ARIAD will also incur somewhat higher sales/marketing expenses as Merck would have compensated Ariad for up to 20 percent of its US sales efforts under the co-promotion agreement.

Actually, that is a very good point - I never really even thought of this (was only really thinking about royalties and other payments owed by Merck). This has got to have some sort of impact on their marketing plans they had with Ponatinib, no? Were they not trying to leverage the Rida salesforce into Ponatinib distribution?